StockNow
CalendarLog in
U.S. Markets

AbbVie (ABBV) extends Migraine leadership with positive Phase 3 Atogepant results in Menstrual Migraine

StockNow breaking-news AI analysis

AbbVie's neuroscience franchise grew 19.8% to $3.23 billion in Q2 2026, with oral CGRP migraine assets Qulipta and Ubrelvy targeting over $5 billion in combined peak sales.

1 stocks
ABBVABBVIE INC.$252.27Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Economy

US PPI PCE Components (Aug.):

Commodities

Iran orders temporary suspension of 10% freight charge on foreign vessels carrying energy products to or from Iran, Fars reports

U.S. Economy

US PPI (Aug MM) 0.4% vs. Exp. 0.4% (Prev. 0.1%)